Managing Resistance to Immune Checkpoint Inhibitors in Lung ...

A proportion of patients with lung cancer experience long-term clinical benefit with immune checkpoint inhibitors (ICIs).

This work reviews the current management and novel treatment strategies for disease progression after ICIs in lung cancer.

Strategies to overcome resistance to immune checkpoint blockade ...

The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), ...

Overcome resistance to immune checkpoint inhibitors in NSCLC

Immune checkpoint inhibitors (ICIs) have transformed the treatment of non-small cell lung cancer (NSCLC). However, resistance occurs in almost all patients.

Overcoming Resistance to Checkpoint Inhibitors with Combination ...

Treatment options for lung cancer have greatly expanded in the last decade. Immune checkpoint inhibitors for patients without driver mutations have become ...

Overcoming immunotherapy resistance in non-small cell lung ...

Immunotherapy (IO) and particularly immune checkpoint inhibitors (ICI), including programmed death receptor 1 (PD-1) and PD-ligand 1 (PD-L1) ...

Clinical characteristics and novel strategies of immune checkpoint ...

Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. ... Immune-checkpoint inhibitor resistance in ...

Resistance to immune checkpoint inhibitors in non-small cell lung ...

Addition of doublet chemotherapy to pembrolizumab in this setting reduces the rate of such primary resistance to 6.9–8.8%, as reported in KEYNOTE 189 and 407.

Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors

Currently, there are several predictive biomarkers of the immune checkpoint inhibitor response; however, no one test appears to be universally predictive and ...

Meeting Immunotherapy Resistance in Lung Cancer

Resistance to immune checkpoint inhibition, either as an initial or acquired event, has become a major challenge in the management of patients with advanced ...

Mechanisms of resistance to immune checkpoint inhibitors - Nature

Whereas cytotoxic chemotherapy and small molecule inhibitors ('targeted therapies') largely act on cancer cells directly, immune checkpoint ...

Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells ...

In the lung, there are two main subtypes of NSCLC, namely, adenocarcinoma and SCC, for which immunotherapy may be a valuable strategy for the treatment of ...

Overcoming acquired resistance to cancer immune checkpoint therapy

Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 to boost tumor-specific T lymphocyte immunity have opened up new avenues ...

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

In adaptive resistance, IFNγ can potentially compromise antitumor immunity by directly upregulating both PD-L1 and PD-L2 on tumor and immune cells (48, 89, 90) ...

Immune checkpoint inhibitors in clinical practice: update on ...

Ipilimumab REMS toxicity management recommends withholding immune checkpoint inhibitor therapy and initiating systemic corticosteroids at 0.5 mg/kg/day ...

Clinical and molecular features of acquired resistance to ...

Several clinical and pre-clinical studies have generated bulk or single-cell RNA-seq datasets to identify gene sets associated with immune checkpoint blockade ( ...

Managing Resistance to Immune Checkpoint Inhibitors in Lung ...

logo. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies · 148. CITATIONS. 148 total citations on Dimensions.

Proliferative potential and resistance to immune checkpoint ...

Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1).

Society for Immunotherapy of Cancer (SITC) consensus definitions ...

Immune checkpoint inhibitors (ICIs) as single agents or in combinations with chemotherapies and targeted therapies are now the standard of care ...

Characteristics and Prognosis of Acquired Resistance to Immune ...

Immune checkpoint inhibitors (ICIs) have become one of the most promising approaches in cancer immunotherapy. In the field of gastrointestinal ( ...